Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Advancing Precision Vaccinology by Molecular and Genomic Surveillance of SARS-CoV-2 in Germany, 2021

ABSTRACT: Molecular and Genomic Surveillance of SARS-CoV-2 in Germany, 2021

PROVIDER: PRJEB50616 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genomic surveillance of human listeriosis in Germany, 2018-2021, closed genomes

Project description:Genomic surveillance of human listeriosis in Germany, 2018-2021, closed genomes

| PRJEB57450 | ENA

Danish SARS-CoV-2 wastewater surveillance, October 2021 - January 2023

Project description:SARS-CoV-2 wastewater surveillance, Denmark 2021-2023

| PRJEB72806 | ENA

Genomic surveillance of human listeriosis in Germany, 2018-2021, 1802 isolate genomes

Project description:Genomic surveillance of human listeriosis in Germany, 2018-2021, 1802 isolate genomes

| PRJEB65895 | ENA

Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021.

Project description:BackgroundComprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern led to an expansion of genomic sequencing activities in Germany.MethodsAt Robert Koch Institute (RKI), the German National Institute of Public Health, we established the Integrated Molecular Surveillance for SARS-CoV-2 (IMS-SC2) network to perform SARS-CoV-2 genomic surveillance at the national scale, SARS-CoV-2-positive samples from laboratories distributed across Germany regularly undergo whole-genome sequencing at RKI.ResultsWe report analyses of 3623 SARS-CoV-2 genomes collected between December 2020 and December 2021, of which 3282 were randomly sampled. All variants of concern were identified in the sequenced sample set, at ratios equivalent to those in the 100-fold larger German GISAID sequence dataset from the same time period. Phylogenetic analysis confirmed variant assignments. Multiple mutations of concern emerged during the observation period. To model vaccine effectiveness in vitro, we employed authentic-virus neutralization assays, confirming that both the Beta and Zeta variants are capable of immune evasion. The IMS-SC2 sequence dataset facilitated an estimate of the SARS-CoV-2 incidence based on genetic evolution rates. Together with modeled vaccine efficacies, Delta-specific incidence estimation indicated that the German vaccination campaign contributed substantially to a deceleration of the nascent German Delta wave.ConclusionsSARS-CoV-2 molecular and genomic surveillance may inform public health policies including vaccination strategies and enable a proactive approach to controlling coronavirus disease 2019 spread as the virus evolves.

| S-EPMC9278222 | biostudies-literature

Bat Lyssavirus Surveillance, Germany 2018-2020

Project description:Enhanced Bat Lyssavirus Surveillance in Germany between 2018-2020

| PRJEB46019 | ENA

Danish SARS-CoV-2 wastewater surveillance

Project description:Data from the Danish SARS-CoV-2 wastewater surveillance

| PRJEB65603 | ENA

Swiss SARS-CoV-2 Wastewater Surveillance

Project description:Surveillance of SARS-CoV-2 genomic variants in wastewater in Switzerland

| PRJEB44932 | ENA

UCSC SARS-CoV-2 Surveillance

Project description:The UCSC Genomics Institute provides molecular and epidemiological data for the molecular surveillance of SARS-CoV-2 in Santa Cruz County.

| PRJEB45618 | ENA

SARS-CoV-2 Genomic Surveillance in Greece

Project description:SARS-CoV-2 Genomic Surveillance in Greece

| PRJEB43435 | ENA

National molecular surveillance of SARS-CoV-2

Project description:National molecular surveillance of SARS-CoV-2

| PRJEB48630 | ENA